Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to announce it has secured a commercialisation agreement with UK-based Precision Healthcare Ltd to market and distribute Creso Pharma’s cannaQIX®10 and 50 hemp-based human health nutraceutical products in the UK.
The UK launch of cannaQIX®10 and 50 is planned for Q1 2018.
Precision Healthcare Ltd is a privately held healthcare company which specialises in the development of consumer healthcare products. It is part of Precision Marketing Group, a leading service provider to international pharmaceutical and healthcare companies. The company sells and distributes consumer healthcare brands to mass retailers and independent pharmacies covering more than 5000 points of sale in the UK.
The agreement covers the non-exclusive marketing and distribution of cannaQIX®10 and 50 in the UK market, targeting pharmacies and health food stores.
cannaQIX® is a unique standardised nutraceutical product, in a proprietary formulation, that contains full plant organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions in humans.
The commercialisation agreement follows Creso receiving confirmation for cannaQIX® as a Food Supplement from the UK Trading Standard Office (TSO), Hertfordshire County Council, as the primary regulatory authority.
Swiss regulatory authorities have issued a certificate of free sales for the export of the product into the UK from Switzerland.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.